Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Core Points - Addex Therapeutics will release its Full-Year 2023 Financial Results on April 18, 2024, with a teleconference and webcast for stakeholders [1] - The company focuses on developing allosteric modulators for neurological disorders, with key drug candidates in various stages of clinical development [3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, ADX71149, is in a Phase 2 clinical study for epilepsy, developed in collaboration with Janssen Pharmaceuticals [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior to advance multiple drug candidates for substance use disorder and is also developing a GABAB PAM program for chronic cough [3] - The company holds a 20% stake in Neurosterix LLC, which is advancing several allosteric modulator programs for various neurological conditions [3] Upcoming Events - A business update and product pipeline review will be provided by CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev during the teleconference on April 18, 2024 [1]